Hangzhou Alltest Biotech Co., Ltd. (688606.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.8x

Market Cap

CNY 3.60B

MomentumView details →

1D Return

−0.67%

YTD Return

—

RSI (14)

44.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.8x

Market Cap

CNY 3.60B

RSI (14)

44.2

MomentumView details →

1D Return

−0.67%

YTD Return

—

ProfitabilityView details →

Gross Margin

50.28%

Net Margin

19.99%

EBITDA Margin

33.31%

ROE (TTM)

4.59%

ROA (TTM)

4.34%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+1.95%

EPS YoY

−44.10%

FCF YoY

−91.32%

Revenue CAGR 3Y

−35.59%

EPS CAGR 3Y

−42.92%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.36x

Quick Ratio

11.51x

Div Yield

4.37%

Div Rate

CNY 2.00

Div Growth 1Y

−60.00%

Financials snapshotView financials →

Revenue (TTM)

892.24M

Net Income (TTM)

178.37M

Op. CF (TTM)

163.67M

Latest newsMore news →

Aotai Bio disclosed its 2026 semi-annual report, reporting revenue of 392 million yuan, down 8.77% year-on-year, and net profit attributable to shareholders of 50.84 million yuan, down 61.48% year-on-year.1d ago

Similar companies

拱东医疗605369.SH Pulse Biosciences, Inc.PLSE 维力医疗603309.SH 康德莱603987.SH OrbusNeich Medical Group Holdings Limited06929.HK ICU Medical, Inc.ICUI Find similar companies →

Latest newsMore news →

Aotai Bio disclosed its 2026 semi-annual report, reporting revenue of 392 million yuan, down 8.77% year-on-year, and net profit attributable to shareholders of 50.84 million yuan, down 61.48% year-on-year.1d ago